A Phase III, Open-label, Randomised Study of Osimertinib With or Without Datopotamab Deruxtecan (Dato-DXd), as First-line Treatment in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer
This study is testing a new combination of cancer medicines to see if it works better than the standard single medicine for a specific type of advanced lung cancer. Researchers want to help patients live longer and keep their cancer under control.
You may be able to join if you are at least 18 years old, have been diagnosed with a specific type of advanced lung cancer with an EGFR gene change, and have not yet received whole-body treatments for your advanced cancer.
Participants will receive either a standard targeted pill alone or the pill combined with a new medicine given through an IV infusion. You will have regular clinic visits every few weeks for check-ups and health assessments as long as the treatment is helping you.
This study is currently recruiting patients at multiple locations in California, United States. The study is actively looking for participants.
- 1Testing a combination of two cancer treatments compared to one
- 2For adults with a specific type of advanced lung cancer
- 3Requires regular clinic visits and health check-ups every few weeks
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.